Public health experts and presidentail staffers express frustration over coronavirus disease 2019 (COVID-19) testing comments made by President Trump; the NIH has halted a clinical trial of hydroxychloroquine after data show no harm or benefit in patients with COVID-19; individuals who have obsessive-compulsive disorder may be at greater risk due to added stress from the pandemic.
Public health experts and staffers from the Trump administration both expressed frustration over comments the President made during a campaign rally on Saturday, in which he said he asked officials to slow down testing for coronavirus disease 2019 (COVID-19). Reported by The Washington Post, experts stress that a crucial part of controlling the pandemic involves increased testing, especially as the virus continues to impact states and is poised to surge in the fall similar to the seasonal flu. Meanwhile, several states that have begun the process of reopening have also seen their daily case totals go up.
On Saturday, the NIH issued a news release stating that it had halted a clinical trial examining the safety and effectiveness of hydroxychloroquine as a COVID-19 treatment, with study data indicating that although the treatment does no harm, it also provides no benefit. Touted by the Trump administration, malaria drug hydroxychloroquine was evaluated by a data and safety monitoring board (DSMB). Following its fourth interim analysis, the DSMB recommended that the National Heart, Lung, and Blood Institute, part of the NIH, stop the trial, which it did immediately.
A piece by Kaiser Health News spotlighted how patients with obsessive-compulsive disorder (OCD) are dealing with additional anxiety precipitated by the pandemic. Nearly 7 in 10 employees indicated in a poll that the pandemic is the most stressful time of their professional career, and at-risk populations, such as those with OCD, may be more inclined to repeat certain behaviors or they may fixate on nonstop intrusive thoughts. However, those who have undergone successful treatment for OCD may be better equipped to accept the pandemic’s uncertainty because their interventions have focused on protecting against the stress of everyday life and the virus.
DLBCL Outcomes Vary Sharply for Patients 80 Years and Older
April 16th 2025A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Complete Responses Seen With Emerging Therapies for Chronic Spontaneous Urticaria
April 16th 2025There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and barzolvolimab showing complete response in patients, particularly among those who are difficult to treat.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More